Yasuo Takehara1, Naoki Kato2, Satoshi Yoshise2, Jean-Sebastien Raynaud3, Philippe Robert3, Claire Corot3, Kazuya Hokamura4, Harumi Sakahara5
1Radiology, Hamamatsu University Hospital, Hamamatsu, Shizuoka, Japan; 2Guerbet Japan, Chiyoda-ku, Tokyo, Japan; 3Guerbet Research, Roissy CDG, Cedex, France; 4Pharmacology, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan; 5Radiology, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan
Under general anesthesia, five VX2 tumor bearing rabbits were examined with contrast enhanced MRI on 3.0T clinical scanner with phased array knee coil. Newly developed USPIO P904 was intravenously administered at a dose of 100 micro mol Fe/kg. Pre and 24 hrs post-contrast MRI was imaged with 3DT2*GRE. Metastatic and non-metastatic popliteal lymph nodes were excised and the specimens were stained with high sensitivity ion stain, macrophage stain and cytokeratin stain. Close histopathological-MRI correlations disclosed that P904 successfully increased the metastatic foci in the lymph node. Newly developed USPIO P904 may be a promising second generation USPIO after ferumoxtran-10.